(19)
(11) EP 2 956 168 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
23.01.2019 Bulletin 2019/04

(45) Mention of the grant of the patent:
25.07.2018 Bulletin 2018/30

(21) Application number: 14751295.8

(22) Date of filing: 14.02.2014
(51) International Patent Classification (IPC): 
A61K 39/295(2006.01)
C07K 19/00(2006.01)
A61K 39/00(2006.01)
C12N 7/00(2006.01)
A61K 39/145(2006.01)
A61P 31/16(2006.01)
A61K 39/12(2006.01)
(86) International application number:
PCT/RU2014/000096
(87) International publication number:
WO 2014/126510 (21.08.2014 Gazette 2014/34)

(54)

POLYVALENT FUSION PROTEIN VACCINE AGAINST INFLUENZA

IMPFSTOFF GEGEN INFLUENZA MIT POLYVALENTEN FUSIONSPROTEINEN

VACCIN CONTRE LA GRIPPE COMPRENANT UNE PROTÉINE DE FUSION POLYVALENTE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 15.02.2013 RU 2013107777

(43) Date of publication of application:
23.12.2015 Bulletin 2015/52

(73) Proprietor: Obshchestvo s Ogranichennoy Otvetstvennostyu "Aktivnye Biosistemy" (OOO "ABS")
197350 Saint-Petersburg (RU)

(72) Inventors:
  • DUKHOVLINOV, Ilya Vladimirovich
    Saint-Petersburg 190068 (RU)
  • ORLOV, Anton Iosifovich
    Saint-Petersburg 194214 (RU)
  • TSYBALOVA, Ljudmila Markovna
    Saint-Petersburg 195299 (RU)
  • KISELEV, Oleg Ivanovich
    Saint-Petersburg 197376 (RU)

(74) Representative: Lapienis, Juozas 
MSP Europe UAB 21-92 Seimyniskiu Str.
09236 Vilnius
09236 Vilnius (LT)


(56) References cited: : 
WO-A2-00/32228
US-A1- 2010 297 174
US-A1- 2012 064 117
RU-C2- 2 358 981
US-A1- 2012 064 117
   
  • TREANOR J J ET AL: "Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults", VACCINE, ELSEVIER LTD, GB, vol. 28, no. 52, 6 December 2010 (2010-12-06), pages 8268-8274, XP027543541, ISSN: 0264-410X [retrieved on 2010-10-20]
  • H. KEIPP TALBOT ET AL: "Immunopotentiation of Trivalent Influenza Vaccine When Given with VAX102, a Recombinant Influenza M2e Vaccine Fused to the TLR5 Ligand Flagellin", PLOS ONE, vol. 5, no. 12, 28 December 2010 (2010-12-28), page e14442, XP055090668, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0014442
  • HULEATT ET AL: "Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin", VACCINE, ELSEVIER LTD, GB, vol. 26, no. 2, 20 November 2007 (2007-11-20), pages 201-214, XP022394779, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2007.10.062
  • MCQUISTON J R ET AL: "Sequencing and comparative analysis of flagellin genes fliC, fljB, and flpA from Salmonella", JOURNAL OF CLINICAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 42, no. 5, 1 May 2004 (2004-05-01), pages 1923-1932, XP002425275, ISSN: 0095-1137, DOI: 10.1128/JCM.42.5.1923-1932.2004
  • WANG BAO-ZHONG ET AL: "Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses", JOURNAL OF VIROLOGY (ONLINE), AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 82, no. 23, 1 December 2008 (2008-12-01), pages 11813-11823, XP009170384, ISSN: 1098-5514
  • LANGZHOU SONG ET AL: "Efficacious Recombinant Influenza Vaccines Produced by High Yield Bacterial Expression: A Solution to Global Pandemic and Seasonal Needs", PLOS ONE, vol. 3, no. 5, 21 May 2008 (2008-05-21), page e2257, XP055090862, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0002257
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).